These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy. Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591 [No Abstract] [Full Text] [Related]
6. Long-term HIV-1 suppression in the Brazilian public health system. de Sa-Filho DJ; de Arruda Souza T; Golegã AA; Diaz RS; Caseiro MM AIDS Patient Care STDS; 2009 May; 23(5):313-4. PubMed ID: 19327023 [No Abstract] [Full Text] [Related]
7. Effect of patient adherence to antiretroviral therapy on CD4+ cell count, HIV-1 RNA, and serum concentrations of tumor necrosis factor and its soluble receptors. Girón-González JA; López-Sánchez A; Elvira J; Perez E; Fernández-Gutiérrez C Eur J Clin Microbiol Infect Dis; 2000 Nov; 19(11):852-8. PubMed ID: 11152310 [TBL] [Abstract][Full Text] [Related]
8. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy. Medeiros RP; Munerato P; Diaz RS J Clin Virol; 2004 Aug; 30(4):346-7. PubMed ID: 15163426 [No Abstract] [Full Text] [Related]
9. Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1-infected cells. Joos B; Fischer M; Opravil M; Ott P; Weber R; Cone RW AIDS; 2000 Apr; 14(6):752-4. PubMed ID: 10807203 [No Abstract] [Full Text] [Related]
10. Antiretroviral resistance. Geretti AM J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209 [No Abstract] [Full Text] [Related]
11. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885 [No Abstract] [Full Text] [Related]
12. Summaries for patients. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and patient outcomes. Ann Intern Med; 2007 Apr; 146(8):I28. PubMed ID: 17438312 [No Abstract] [Full Text] [Related]
13. Lymphoid tissue viral burden and duration of viral suppression in plasma. Martínez E; Arnedo M; Giner V; Gil C; Caballero M; Alós L; García F; Holtzer C; Mallolas J; Miró JM; Pumarola T; Gatell JM AIDS; 2001 Aug; 15(12):1477-82. PubMed ID: 11504979 [TBL] [Abstract][Full Text] [Related]
14. Lack of significant viral load alterations of hepatitis B virus and hepatitis C virus during treatment with IL-2 and highly active antiretroviral therapy. Hengge UR; Roggendorf M; Goos M AIDS; 2000 Nov; 14(16):2617-9. PubMed ID: 11101079 [No Abstract] [Full Text] [Related]
15. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551 [TBL] [Abstract][Full Text] [Related]
16. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication. Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634 [TBL] [Abstract][Full Text] [Related]
17. Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels. Sha BE; Johnson VA; Kendall MA; Haubrich R; Nokta M; Lamb K; Zackin RA; Nail CD; Currier JS AIDS; 2000 Apr; 14(6):746-8. PubMed ID: 10807200 [No Abstract] [Full Text] [Related]